多替阿巴拉米片治疗艾滋病效果如何？

On January 22, 2018, GlaxoSmithKline (GSK) announced that its single-pill combination preparation (Triumeq) based on the new generation integrase inhibitor dolutegravir (DTG) for the treatment of HIV was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China.

How effective is doteabalamid tablets in treating AIDS?

The effectiveness of this product in treating treatment-naïve HIV-infected subjects was based on an analysis of data from two randomized, international, double-blind, active-controlled trials, SINGLE (ING114467) and SPRING-2 (ING13086), and one international, open-label, active-controlled trial, FLAMINGO (ING114915).

In SINGLE, 833 patients were treated with dolutegravir 50 mg once daily plus fixed-dose abacavir-lamivudine (DTG - ABC/3TC) or fixed-dose efavirenz-tenofodoxine-emtricitabine (EFV/TDF/FTC). At baseline, the median age of patients was 35 years, 16% were female, 32% were nonwhite, 7% were co-infected with hepatitis C virus, and 4% were CDC category C. These characteristics were similar between the two treatment groups.

In the 48-week primary analysis, the proportion of patients achieving virological suppression was higher in the dolutegravir ABC/3TC group than in the FTC/TDF/ETC group, p=0.003. The same treatment difference was observed among subjects defined by baseline HIV RNA levels (or 100,000 copies/ml). The median time to virological suppression was shorter in the ABC/3TC DTG group. (28 days and 84 days respectively, p<0.0001). Relative to the baseline period, the adjusted mean changes in CD4 cell counts were 267 cells and 208 cells/mm' (p<0.001). Analyzes of time to attainment of virological suppression and change from baseline were prespecified and adjusted for multiplicity. At week 96, responses were 80% and -72%, respectively. The end point difference is still statistically significant (p=0.006). The statistically higher response in the DTG ABC/3TC group was primarily due to a higher proportion of withdrawals due to adverse events in the FTC/TDF/FTC group, independent of viral load stratification. Overall treatment differences at week 96 applied to patients with higher and lower baseline viral loads. Patients could maintain virological suppression during the 1440 weeks of the SINGLE open period, and the DTG ABC/3TC group (71%) was better than the EFV/TDF/FTC group (63%), with a treatment difference of 8.3% (2.0, 14.6).

The proportion of withdrawals due to adverse events was higher in the FTC/TDF/FTC group, regardless of viral load stratification. Overall treatment differences at week 96 applied to patients with higher and lower baseline viral loads. Patients could maintain virological suppression during the 1440 weeks of the SINGLE open period, and the DTGXxXABC/3TC group (71%) was better than the EFV/TDF/FTC group (63%), with a treatment difference of 8.3% (2.0, 14.6). Judging from research data, the treatment of patients infected with human immunodeficiency virus (HIV) has good safety and effectiveness.